Latest Market Diversification News

Page 4 of 4

Bubs Australia Posts $2.9m EBITDA Turnaround, Eyes FDA Approval in 2025

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

Eva Park

22 Jan 2025

Top